A randomized phase III trial evaluating the role of axillary lymph node dissection in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy

Protocol: 
AAAO0763
Phase: 
III

A randomized phase III trial evaluating the role of axillary lymph node dissection in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy

Patients with your type of breast cancer usually have neoadjuvant (which means “given before surgery) chemotherapy followed by breast and arm pit surgery to remove any remaining breast cancer. The lymph nodes in the arm pit are examined during surgery and if there is still cancer in the lymph nodes, then the majority of lymph nodes in the arm pit are removed. The purpose of this study is to examine whether removing some of the lymph nodes from the arm pit, but not removing them all followed with radiation therapy (experimental) will be as good as having the majority of the lymph nodes from the arm pit removed during breast surgery followed with radiation (standard of care).

Are you Eligible? (Inclusion Criteria)

-Breast cancer that has spread to the lymph nodes under the arm (in arm pit)
-Previously treated with chemotherapy before having surgery to remove any remaining breast cancer

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States